Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Clin Cancer Res. 2019 Jul 1;25(13):4049-4062. doi: 10.1158/1078-0432.CCR-18-3516. Epub 2019 Mar 19.
Clin Cancer Res. 2019.
PMID: 30890549
AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress.
Villafañez F, García IA, Carbajosa S, Pansa MF, Mansilla S, Llorens MC, Angiolini V, Guantay L, Jacobs H, Madauss KP, Gloger I, Gottifredi V, Bocco JL, Soria G.
Villafañez F, et al. Among authors: guantay l.
Oncogene. 2019 May;38(22):4310-4324. doi: 10.1038/s41388-019-0724-7. Epub 2019 Jan 31.
Oncogene. 2019.
PMID: 30705406
Free PMC article.
Item in Clipboard
Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
Guantay L, Garro C, Siri S, Pansa MF, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Jansson KH, Remlinger K, Amador A, Stronach E, Coleman K, Muelbaier M, Drewes G, Gloger I, Madauss K, García M, Gottifredi V, Soria G.
Guantay L, et al.
Drug Resist Updat. 2023 Mar;67:100932. doi: 10.1016/j.drup.2023.100932. Epub 2023 Jan 22.
Drug Resist Updat. 2023.
PMID: 36706533
Item in Clipboard
Cite
Cite